Research is being conducted on the use of PROTACs, a targeted protein degradation strategy, in the treatment of various cancers, including leukemia. Studies are exploring the design, synthesis, and activity of PROTACs in different models, including primary leukemia cells and patient-derived xenograft models. The potential of PROTACs as a cancer therapy is being investigated, with some studies focusing on their use in combination with other treatments to enhance their effectiveness.